1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
https://artivion.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 1,500
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. James Patrick Mackin | Chairman, President & CEO | 2.37M | 194.62k | 1967 |
Mr. Lance A. Berry CPA | Executive VP of Finance, COO & CFO | 138.36k | N/D | 1972 |
Ms. Amy D. Horton CPA | VP & Chief Accounting Officer | 621.26k | 118.2k | 1970 |
Ms. Jean F. Holloway Esq. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 841.43k | N/D | 1957 |
Mr. John E. Davis | Senior VP & Chief Commercial Officer | 802.02k | 27.55k | 1965 |
Mr. Matthew A. Getz | VP of Human Resources & Chief Human Resources Officer | N/D | N/D | 1969 |
Dr. Marshall S. Stanton M.D. | Senior VP of Clinical Research & Chief Medical Officer | 615.55k | N/D | 1957 |
Dr. Robert C. Thomson | Vice President of Research & Development | N/D | N/D | 1970 |
Mr. Florian Tyrs | Vice President of Global Operations | N/D | N/D | N/D |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
La calificación ISS Governance QuickScore de Artivion, Inc. a partir del 1 de octubre de 2024 es 4. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 4; Compensación: 4.